The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer

An optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with sy...

Full description

Bibliographic Details
Main Authors: Ryoji Takada, Kenji Ikezawa, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai, Takuo Yamai, Nobuyasu Fukutake, Tasuku Nakabori, Hiroyuki Uehara, Reiko Ashida, Hirofumi Akita, Hidenori Takahashi, Teruki Teshima, Kazuyoshi Ohkawa
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
pancreatic ductal adenocarcinoma
chemoradiation
induction chemotherapy
conversion surgery
combination chemotherapy
local response
Online Access:https://www.mdpi.com/2072-6694/13/18/4733

Internet

https://www.mdpi.com/2072-6694/13/18/4733

Similar Items